Number of the records: 1  

Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009-2014)

  1. 1.
    SYSNO ASEP0448652
    Document TypeJ - Journal Article
    R&D Document TypeJournal Article
    Subsidiary JČlánek ve WOS
    TitleCyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009-2014)
    Author(s) Malínková, Veronika (UEB-Q) ORCID, RID
    Vylíčil, Jakub (UEB-Q)
    Kryštof, Vladimír (UEB-Q) RID, ORCID
    Source TitleExpert Opinion on Therapeutic Patents - ISSN 1354-3776
    Roč. 25, č. 9 (2015), s. 953-970
    Number of pages18 s.
    Languageeng - English
    CountryGB - United Kingdom
    Keywordscancer ; CDK ; cyclin
    Subject RIVEB - Genetics ; Molecular Biology
    R&D ProjectsLO1204 GA MŠMT - Ministry of Education, Youth and Sports (MEYS)
    ED3.1.00/14.0327 GA MŠMT - Ministry of Education, Youth and Sports (MEYS)
    GA15-15264S GA ČR - Czech Science Foundation (CSF)
    Institutional supportUEB-Q - RVO:61389030
    UT WOS000361269100002
    DOI10.1517/13543776.2015.1045414
    AnnotationIntroduction: Cell cycle deregulation is a common characteristic of cancer cells. Progression through the cell cycle is controlled by enzymes known as cyclin-dependent kinases (CDKs), whose activity can be upregulated by a wide range of molecular mechanisms. Based on these observations, small molecule CDK inhibitors are being developed as potential cancer therapeutics. Some of these compounds have entered Phase Ill clinical trials and one of them, palbociclib, recently received accelerated approval from the FDA. However, the complexity of CDK biology and the undesired side effects of the existing inhibitors mean that the hunt for new CDK-targeting drug candidates continues. Areas covered: This article reviews patent applications related to small molecule CDK inhibitors published between 2009 and 2014. Expert opinion: Clinical trials with pan-specific inhibitors have generally yielded unambiguously positive outcomes. However, better results have been achieved with highly specific inhibitors of CDK4/CDK6. This may be due to several factors and has generated considerable interest in the discovery of new mono-specific CDK inhibitors. The development of such compounds is challenging because all CDKs have very similar active sites. Aside from this issue of selectivity, another key challenge is the identification of patients who will benefit from specific therapies.
    WorkplaceInstitute of Experimental Botany
    ContactDavid Klier, knihovna@ueb.cas.cz, Tel.: 220 390 469
    Year of Publishing2016
Number of the records: 1  

  This site uses cookies to make them easier to browse. Learn more about how we use cookies.